• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Walgreens Appoints Jason Stenta as SVP and Chief Commercial Officer

    10/7/24 8:00:00 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $WBA alert in real time by email

    Stenta will lead B2B commercial growth strategy as the company strengthens its role as the first choice for community pharmacy and health services in the U.S.

    Walgreens, an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, today announced the appointment of Jason Stenta as SVP and chief commercial officer. In this new role, Stenta will lead the company's commercial growth strategy, driving development and commercialization of B2B healthcare services built on the company's core assets, and enhancing partnerships with payers, health system providers and life sciences companies.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241007453700/en/

    Jason Stenta, SVP & Chief Commercial Officer (Photo: Business Wire)

    Jason Stenta, SVP & Chief Commercial Officer (Photo: Business Wire)

    "Jason is a strategic, relationship-driven healthcare leader, and I'm proud to welcome him to the team," said Mary Langowski, EVP and president, U.S. Healthcare, at Walgreens Boots Alliance. "His experience with complex healthcare organizations, along with his strong understanding of market dynamics, regulatory requirements, and customer needs, will be invaluable as we strengthen our relationships and solutions in healthcare."

    Stenta brings nearly 20 years of healthcare experience, successfully leading large organizations and cross-functional teams through growth and change. Most recently, he was at Optum, a UnitedHealth Group company, where he served as SVP, payer sales. Prior to Optum, he held leadership roles at CVS Health for 10 years.

    "This is an exciting time at Walgreens, and I'm thrilled to have this unique opportunity to contribute," said Stenta. "As we look to expand services, and provide partners with healthcare solutions they really need, I believe Walgreens core strengths and services in retail pharmacy will be key in how we're able to do this."

    Stenta will begin his new role in early October.

    About Walgreens

    Walgreens (www.walgreens.com) is included in the U.S. Retail Pharmacy and U.S. Healthcare segments of Walgreens Boots Alliance, Inc. (NASDAQ:WBA), an integrated healthcare, pharmacy and retail leader. True to its purpose of "more joyful lives through better health," Walgreens has a more than 120-year heritage of caring for communities and providing trusted pharmacy services, and today is playing a greater role as an independent partner of choice offering healthcare services that improve care, lower costs, and help patients. Operating nearly 9,000 retail locations across the U.S. and Puerto Rico, Walgreens is proud to serve nearly 9 million customers and patients daily. The company's pharmacists are playing a more critical role in healthcare than ever before, providing a wide range of pharmacy and healthcare services, including those that drive equitable access to care for some of the nation's most underserved populations. Walgreens offers customers and patients a true omnichannel experience, with fully integrated physical and digital platforms designed to deliver high-quality products and healthcare services. Within the U.S. Healthcare segment, Walgreens portfolio also includes businesses in primary care, multi-specialty, post-acute care, urgent care, specialty pharmacy services, population health and provider enablement.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241007453700/en/

    Get the next $WBA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $WBA

    DatePrice TargetRatingAnalyst
    2/28/2025$11.00 → $9.00Hold → Sell
    Deutsche Bank
    2/26/2024$23.00Market Perform
    Leerink Partners
    2/20/2024Hold → Reduce
    HSBC Securities
    1/3/2024$21.00Underweight
    Barclays
    12/22/2023$27.00Hold
    HSBC Securities
    10/23/2023$27.00 → $30.00Neutral → Overweight
    JP Morgan
    7/3/2023$37.00 → $27.00Underweight
    Morgan Stanley
    6/28/2023$46.00 → $34.00Buy → Hold
    Deutsche Bank
    More analyst ratings

    $WBA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Global CLO & Corp. Sec. Minnix Lanesha covered exercise/tax liability with 19,135 shares, decreasing direct ownership by 5% to 348,093 units (SEC Form 4)

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      6/3/25 9:16:29 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • EVP, President U.S. Healthcare Langowksi Mary covered exercise/tax liability with 40,304 shares, decreasing direct ownership by 8% to 494,295 units (SEC Form 4)

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      6/3/25 9:12:39 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • EVP, Global Chief HR Officer Burger Elizabeth covered exercise/tax liability with 16,495 shares, decreasing direct ownership by 5% to 303,875 units (SEC Form 4)

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      6/3/25 9:08:21 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Walgreens and KFF's Greater Than Campaign to Offer Free HIV/STD Testing in Stores on June 27

      More than 415 local health departments and community organizations mobilize across the country for largest-ever National HIV Testing Day event Walgreens and Greater Than HIV/STDs, a public information campaign from KFF, are joining with health departments and community organizations to provide free rapid HIV, syphilis and hepatitis C testing at more than 575 Walgreens stores on June 27 for the nation's largest National HIV Testing Day (NHTD) event. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612760766/en/ With more than 415 local testing partners in nearly all states, Washington, D.C. and Puerto Rico, this year's activat

      6/12/25 9:00:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • LiveRamp and Walgreens Advertising Group Deliver Business Growth for Advertisers Through Robust Data Collaboration Partnership

      WAG advertisers can now accelerate audience creation, activation, and measurement with flexibility and speed LiveRamp (NYSE:RAMP), the leading data collaboration partner, today announced it is powering Walgreens Advertising Group's (WAG) clean room solution. The partnership enables WAG, the retail media division of Walgreens, to increase access to its first-party data at speed, scale audience insights, and offer more transparency and control to advertisers. This enables brands to enhance media measurement across all platforms in the digital ecosystem and improve ROI with faster time-to-value. LiveRamp's data collaboration network enables WAG to unlock new insights, accelerate performanc

      6/11/25 5:30:00 AM ET
      $RAMP
      $WBA
      EDP Services
      Technology
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Walgreens Expands Micro-Fulfillment Network with New Facility in Brooklyn Park, Minnesota

      The facility will support nearly 200 stores regionally with the dispensing and shipping of prescriptions, allowing pharmacists to spend more time with patients. Walgreens is continuing to invest in innovative pharmacy solutions with the opening of a new micro-fulfillment center (MFC) in Brooklyn Park, Minnesota. This facility will streamline prescription processing and reduce administrative tasks, freeing up pharmacists to focus more on delivering personalized care to their patients. This new facility will support nearly 200 Walgreens stores across the Midwest, including 145 in Minnesota alone, and is expected to process approximately 13 million prescriptions each year. It will also bring

      5/20/25 9:00:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Executive Chairman of Board Pessina Stefano sold $9,163,161 worth of shares (832,258 units at $11.01) and bought $9,163,161 worth of shares (832,258 units at $11.01), decreasing direct ownership by 56% to 657,308 units (SEC Form 4)

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      4/29/25 8:49:21 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Bhandari Inderpal S bought $54,150 worth of shares (3,000 units at $18.05) (SEC Form 4)

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      4/15/24 5:45:26 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Mahajan Manmohan bought $116,280 worth of shares (6,000 units at $19.38) (SEC Form 4)

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      4/2/24 6:40:23 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Walgreens Boots Alliance downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded Walgreens Boots Alliance from Hold to Sell and set a new price target of $9.00 from $11.00 previously

      2/28/25 7:36:45 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Leerink Partners initiated coverage on Walgreens Boots Alliance with a new price target

      Leerink Partners initiated coverage of Walgreens Boots Alliance with a rating of Market Perform and set a new price target of $23.00

      2/26/24 8:28:07 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Walgreens Boots Alliance downgraded by HSBC Securities

      HSBC Securities downgraded Walgreens Boots Alliance from Hold to Reduce

      2/20/24 10:23:30 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Walgreens Boots Alliance Inc.

      DEFA14A - Walgreens Boots Alliance, Inc. (0001618921) (Filer)

      6/17/25 4:05:47 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form DEFA14A filed by Walgreens Boots Alliance Inc.

      DEFA14A - Walgreens Boots Alliance, Inc. (0001618921) (Filer)

      6/13/25 4:05:18 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form DEFA14A filed by Walgreens Boots Alliance Inc.

      DEFA14A - Walgreens Boots Alliance, Inc. (0001618921) (Filer)

      6/12/25 4:24:00 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • September 12, 2023 - FDA Issues Warning Letters to Firms Marketing Unapproved Eye Products

      For Immediate Release: September 12, 2023 The U.S. Food and Drug Administration has issued warning letters to eight companies for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law. These warning letters are part of the agency’s ongoing effort to protect Americans from potentially harmful ophthalmic products. Eye products addressed in the eight warning letters are illegal

      9/12/23 10:44:21 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    Leadership Updates

    Live Leadership Updates

    See more
    • Walgreens Appoints Jason Stenta as SVP and Chief Commercial Officer

      Stenta will lead B2B commercial growth strategy as the company strengthens its role as the first choice for community pharmacy and health services in the U.S. Walgreens, an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, today announced the appointment of Jason Stenta as SVP and chief commercial officer. In this new role, Stenta will lead the company's commercial growth strategy, driving development and commercialization of B2B healthcare services built on the company's core assets, and enhancing partnerships with payers, health system providers and life sciences companies. This press release features multimedia. View the full release

      10/7/24 8:00:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Walgreens Appoints Two New Leaders to its Retail and Customer Experience Team

      Names Tracey Koller as Chief Merchandising Officer and Sharmila Sudhakar as Group Vice President and Head of Digital Commerce Walgreens, the leading independent retail pharmacy and healthcare provider, today announced two key leadership appointments: Tracey Koller, senior vice president and chief merchandising officer, and Sharmila Sudhakar, group vice president and head of Walgreens digital commerce. The company believes these new appointments will significantly contribute to its efforts with regard to the turnaround of the business as the company focuses on enhancing the front of store and omnichannel experience for its customers while driving in-store efficiencies. This press release

      8/16/24 9:00:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Super Micro Computer Inc. to Join the Nasdaq-100 Index® Beginning July 22, 2024

      NEW YORK, July 12, 2024 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Super Micro Computer Inc. (NASDAQ:SMCI), will become a component of the Nasdaq-100 Index® (NASDAQ:NDX) and the Nasdaq-100 Equal Weighted™ Index (NASDAQ:NDXE) prior to market open on Monday, July 22, 2024. Super Micro Computer Inc. will replace Walgreens Boots Alliance Inc. (NASDAQ:WBA) in the Nasdaq-100 Index® and the Nasdaq-100 Equal Weighted Index. Walgreens Boots Alliance Inc. will also be removed from the Nasdaq-100 Ex-Tech Sector™ Index (NASDAQ:NDXX), the Nasdaq-100 ESG™ Index (NASDAQ:NDXESG), and the Nasdaq-100 Sustainable ESG Select™ Index (NASDAQ:NDXSES) on the same date. Super Micro Computer Inc

      7/12/24 8:00:00 PM ET
      $NDAQ
      $SMCI
      $WBA
      Investment Bankers/Brokers/Service
      Finance
      Computer Manufacturing
      Technology

    $WBA
    Financials

    Live finance-specific insights

    See more
    • Walgreens Boots Alliance Reports Fiscal 2025 Second Quarter Results

      Second quarter financial results Second quarter loss per share1 was $3.30 compared to loss per share of $6.85 in the year-ago quarter. Second quarter results include $4.2 billion of non-cash impairment charges attributable to WBA, net of tax and non-controlling interest, related to goodwill, intangible and other long-lived assets primarily at U.S. Retail Pharmacy and VillageMD, and $1.0 billion of after-tax gains related to asset monetization activities. Adjusted earnings per share (EPS)2 was $0.63 compared to adjusted EPS2 of $1.20 in the year-ago quarter. The decline in adjusted EPS2 was primarily driven by prior year adjusted effective tax benefit2, lower U.S. retail sales and prior

      4/8/25 7:00:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Walgreens Boots Alliance Early-Settles Certain Prepaid Variable Share Forward Transactions and Sells Related Shares of Cencora For Approximately $300 Million of Proceeds

      Transaction Highlights Walgreens Boots Alliance announces early settlement of certain prepaid variable share forward transactions with respect to shares of Cencora for delivery of an aggregate 6.1 million shares Concurrent with the early settlement, the Company executed a sale of the remaining 1.3 million shares of Cencora pledged under the early settled contracts. The Company receives approximately $300 million from the early settlement and the concurrent sale of shares Following today's early settlement, the Company owns approximately 12.6 million shares of Cencora pledged under the remaining prepaid variable share forward contracts, which have the potential to provide additional

      2/6/25 8:30:00 PM ET
      $COR
      $WBA
      Other Pharmaceuticals
      Health Care
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Walgreens Boots Alliance Suspends Quarterly Dividend as Company Continues Disciplined Execution Against Strategic Priorities

      Walgreens Boots Alliance, Inc. (NASDAQ:WBA) today announced that its board of directors is suspending the company's cash dividend historically paid to stockholders on a quarterly basis, as management continues to evaluate and refine its capital allocation policy consistent with the company's broader long-term turnaround efforts. This change in capital allocation is aimed at strengthening WBA's balance sheet by reducing debt over time and improving free cash flow, as the company works toward achieving a retail pharmacy-led turnaround underpinned by a sustainable economic model. The company's cash needs over the next several years, including with respect to litigation and debt refinancing,

      1/30/25 4:55:00 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Walgreens Boots Alliance Inc.

      SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)

      10/18/24 12:45:41 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Amendment: SEC Form SC 13D/A filed by Walgreens Boots Alliance Inc.

      SC 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Filed by)

      8/20/24 4:05:58 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form SC 13G/A filed by Walgreens Boots Alliance Inc. (Amendment)

      SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)

      2/13/24 5:17:30 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples